< Back to previous page
Researcher
Maria Debiec-Rychter
- Disciplines:Genetics, Systems biology, Molecular and cell biology
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Member
From1 Jul 2009 → Today - Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Jun 2009
Projects
1 - 4 of 4
- Human soft tissue sarcomas xenograft mouse models as an opportunity to improve the therapeutic options for patients.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project
- Identification of novel protein kinase targets for the improvement of gastrointestinal stromal tumor (GIST) therapy: a paradigm for the optimisation of kinase targeted therapies.From1 Jan 2011 → 31 Dec 2016Funding: FWO research project
- Deregulated signaling pathways in cancer: from genetic insights towards targeted therapy.From1 Oct 2010 → 30 Nov 2016Funding: BOF - Concerted Research Project from 1994
- The biological and therapeutic importance of CCK-2/gastrin receptor in gastrointestinal stromal tumors (GISTs).From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
Publications
31 - 40 of 194
- Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial(2018)
Authors: Patrick Schöffski, Maria Debiec-Rychter, Raf Sciot, Agnieszka Wozniak
Pages: 431 - 441 - Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma(2018)
Authors: Lien Spans, Maria Debiec-Rychter
Pages: 2688 - 2699 - A rare case of atypical/anaplastic meningioma with MDM2 amplification(2018)
Authors: Maria Debiec-Rychter, Raf Sciot
- The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'(2018)
Authors: Patrick Schöffski, Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot
Pages: 156 - 167 - Primary myxoid mesenchymal tumor with intracranial location: report of a case with a EWSR1-ATF1 fusion(2018)
Authors: Raf Sciot, Sandra Jacobs, Frank Van Calenbergh, Philippe Demaerel, Agnieszka Wozniak, Maria Debiec-Rychter
Pages: 880 - 883 - Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE"(2018)
Authors: Patrick Schöffski, Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot
Pages: 758 - 765 - Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway(2018)
Authors: Maria Debiec-Rychter
Pages: 388 - 393 - BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas(2018)
Authors: Maria Debiec-Rychter
Pages: 335 - 341 - Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center(2018)
Authors: Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Ignace Vergote, Patrick Schöffski
Pages: 206 - 213 - Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial(2017)
Authors: Patrick Schöffski, Agnieszka Wozniak, Evelyne Lerut, Maria Debiec-Rychter
Pages: 147 - 163